

NVP-ACC789

Catalog No: tcsc0015997

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Specifications

CAS No:

300842-64-2

Formula:

 $\mathsf{C}_{21}^{}\mathsf{H}_{17}^{}\mathsf{BrN}_{4}^{}$

Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

Target:

VEGFR;PDGFR

Purity / Grade:

>98%

Solubility:

DMSO : 60 mg/mL (148.04 mM; Need ultrasonic and warming)

Alternative Names:

ACC-789;ZK202650

Observed Molecular Weight:

405.29

Copyright 2021 Taiclone Biotech Corp.




Product Description

NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR- β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μ M, respectively.

IC50 & Target: IC50: 0.38 μ M (human VEGFR-1), 0.02 μ M (human VEGFR-2), 0.23 μ M (mouse VEGFR-2), 0.18 μ M (human VEGFR-3), 1.4 μ M (human PDGFR- β)^[1]

In Vitro: The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR- β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μ M, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μ M. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μ M, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC₅₀ of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μ M^[1].

In Vivo: NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.